These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21083069)

  • 21. Biotech jostles with pharma for slice of HIV market.
    Katsnelson A
    Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
    [No Abstract]   [Full Text] [Related]  

  • 22. Biotechnology at Yale.
    Shiao S
    Yale J Biol Med; 2001; 74(3):197-9. PubMed ID: 11501716
    [No Abstract]   [Full Text] [Related]  

  • 23. Biotechnology--the enormous cost of success.
    Levy R
    N Engl J Med; 1991 Oct; 325(16):1177-8. PubMed ID: 1891031
    [No Abstract]   [Full Text] [Related]  

  • 24. Biotechnology. Mixed reactions to merger.
    Gershon D
    Nature; 1990 Feb; 343(6260):681. PubMed ID: 2304541
    [No Abstract]   [Full Text] [Related]  

  • 25. Market access for biopharmaceuticals: new challenges.
    Simon F
    Health Aff (Millwood); 2006; 25(5):1363-70. PubMed ID: 16966734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
    Reed SD; Califf RM; Schulman KA
    Health Aff (Millwood); 2006; 25(5):1309-17. PubMed ID: 16966727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biotechnology company's shares dive 67% after drug failure.
    Dobson R
    BMJ; 2000 Oct; 321(7268):1039. PubMed ID: 11053161
    [No Abstract]   [Full Text] [Related]  

  • 28. Early-stage returns?
    Booth BL
    Nat Biotechnol; 2006 Nov; 24(11):1335-40. PubMed ID: 17093473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biotechnology in Ireland: hard work, money and the brain gain.
    O'Neill MF
    Drug Discov Today; 2007 Feb; 12(3-4):108-11. PubMed ID: 17275730
    [No Abstract]   [Full Text] [Related]  

  • 30. This Dutchman is flying.
    Watson N
    Fortune; 2003 Jun; 147(13):89-90. PubMed ID: 12827720
    [No Abstract]   [Full Text] [Related]  

  • 31. Big pharma swallows biotech's pride.
    Huggett B
    Nat Biotechnol; 2008 Sep; 26(9):955-6. PubMed ID: 18779785
    [No Abstract]   [Full Text] [Related]  

  • 32. Amgen's big-ticket play for Immunex.
    Fletcher L
    Nat Biotechnol; 2002 Feb; 20(2):105-6. PubMed ID: 11821840
    [No Abstract]   [Full Text] [Related]  

  • 33. Japanese firms broaden investment focus to early biotech.
    Louët S; Sipp D
    Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
    [No Abstract]   [Full Text] [Related]  

  • 34. Sunbaked biotechnology in Australia.
    Littlejohn T
    Nat Biotechnol; 2002 Sep; 20(9):873-7. PubMed ID: 12205502
    [No Abstract]   [Full Text] [Related]  

  • 35. Overcoming the challenges in the pharma/biotech industry.
    Graul AI; Prous JR
    Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bad medicine.
    Sheridan C
    Nat Biotechnol; 2007 Jul; 25(7):707-9. PubMed ID: 17621284
    [No Abstract]   [Full Text] [Related]  

  • 37. Financial Times Global Pharmaceutical & Biotechnology Conference 2009.
    Scattereggia J
    IDrugs; 2010 Jan; 13(1):26-9. PubMed ID: 20024844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Will this experiment work?
    Kadlec D
    Time; 2003 Jul; 162(1):80-1. PubMed ID: 14584341
    [No Abstract]   [Full Text] [Related]  

  • 39. Deal watch: recent trends in deal-making.
    Dawkes A; Papp T
    Nat Rev Drug Discov; 2010 Dec; 9(12):909. PubMed ID: 21119724
    [No Abstract]   [Full Text] [Related]  

  • 40. The worst of times, the best of times.
    Nat Biotechnol; 2009 Feb; 27(2):101. PubMed ID: 19204667
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.